1 / 8

Lancet 2, 1021, 1983

Peptides from Scorpion Venom and Autoimmune diseases K. George Chandy, Department of Physiology and Biophysics, University of California Irvine. Lancet 2, 1021, 1983.

asta
Download Presentation

Lancet 2, 1021, 1983

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Peptides from Scorpion Venom and Autoimmune diseasesK. George Chandy, Department of Physiology and Biophysics, University of California Irvine

  2. Lancet 2, 1021, 1983

  3. The authors of the Lancet Letter suggest that the improvement is due to improved nerve conduction. But would such an improvement of nerve conduction result in a 2 month remission of MS? Is it possible that scorpion venom blocked Kv1.3 potassium channels in disease-associated myelin-specific effector-memory T cells in this patient, suppressed the autoimmune response and thereby produced the remission of MS? Kv1.3 channels in effector memory T cells are considered an attractive and safe target for autoimmune disease therapy. Wulff et al, J Clin Invest. 2003;111:1703-13; Chandy et al., Trends Pharmacol Sci. 2004;25:280-9; Rus et al., Proc Natl Acad Sci U S A. 2005;102:11094-9; Beeton et al., Proc Natl Acad Sci U S A. 2006;103:17414-9.

  4. Scorpion toxins block the Kv1.3 channel Toxin: IC50 ADWX-1 toxin: 1 pM HsTx1: 12 pM OSK1 toxin: 14 pM Pi2: 50 pM Hongotoxin: 86 pM Margatoxin: 110 pM Agitoxin-2: 200 pM Pi3: 500 pM Kaliotoxin: 650 pM Anuroctoxin: 760 pM Noxiustoxin: 1000 pM Aam-KTX: 1100 pM Hemitoxin: 2000 pM Charybdotoxin: 3000 pM Tityustoxin-Ka: 4000 pM Css20: 7200 pM Pi1: 11000 pM Kbot1: 15000 pM LmKTx10: 28000 pM Maurotoxin: 150000 pM Parabuthus Tx3: 492000 pM Parabuthus Tx1: 800000 pM J Gen Physiol. 1989;93:1061-74. Proc Natl Acad Sci U S A. 1989;86:10171-5. J Biol Chem. 1991;266:3668-74. J Biol Chem. 1993;268:18866-74. Biochem Biophys Res Commun. 1994;198:619-25. Neuron. 1995;15:1169-81. J Immunol. 1997;158:5120-8 J Biol Chem. 1998;273:2639-44. Biochem Biophys Res Commun. 2000;278:34-7. Mol Pharmacol. 2005;67:1034-44. Mol Pharmacol. 2006;69:354-62. J Biol Chem. 2008;283:19058-65.

  5. Kv1.3 blockers from scorpion venom are immunosuppressive Price M. et al., Charybdotoxin inhibits proliferation and interleukin 2 production in human peripheral blood lymphocytes. Proc Natl Acad Sci U S A. 1989;86:10171-5. Freedman BD et al., Evidence for voltage modulation of IL-2 production in mitogen-stimulated human peripheral blood lymphocytes. J Immunol. 1992;149:3784-94. Lin CS, et al. Voltage-gated potassium channels regulate calcium-dependent pathways involved in human T lymphocyte activation. J Exp Med. 1993;177:637-45. Koo GC et al., Blockade of the Voltage-gated potassium channel Kv1.3 inhibits immune responses in vivo. J Immunol. 1997;158:5120-8. Beeton C, et al. Selective blocking of voltage-gated K+ channels improves experimental autoimmune encephalomyelitis and inhibits T cell activation. J Immunol. 2001;166:936-44.

  6. Kv1.3 blockers from scorpion venom are effective in a rat model of multiple sclerosis Beeton C, et al. Selective blocking of voltage-gated K+ channels improves experimental autoimmune encephalomyelitis and inhibits T cell activation. J Immunol. 2001;166:936-44. Kaliotoxin (KTX), a blocker of voltage-gated potassium channels (Kv), is highly selective for Kv1.1 and Kv1.3. First, Kv1.3 is expressed by T lymphocytes. Blockers of Kv1.3 inhibit T lymphocyte activation. Second, Kv1.1 is found in paranodal regions of axons in the central nervous system. Kv blockers improve the impaired neuronal conduction of demyelinated axons in vitro and potentiate the synaptic transmission. Therefore, we investigated the therapeutic properties of KTX via its immunosuppressive and symptomatic neurological effects, using experimental autoimmune encephalomyelitis (EAE), an animal model for multiple sclerosis. The T line cells used to induce adoptive EAE were myelin basic protein (MBP)-specific, constitutively contained mRNA for Kv1.3. and expressed Kv1.3. These channels were shown to be blocked by KTX. Activation is a crucial step for MBP T cells to become encephalitogenic. The addition of KTX during Ag-T cell activation led to a great reduction in the MBP T cell proliferative response, in the production of IL-2 and TNF, and in Ca(2+) influx. Furthermore, the addition of KTX during T cell activation in vitro led a decreased encephalitogenicity of MBP T cells. Moreover, KTX injected into Lewis rats impaired T cell function such as the delayed-type hypersensitivity. Lastly, the administration of this blocker of neuronal and lymphocyte channels to Lewis rats improved the symptoms of EAE. We conclude that KTX is a potent immunosuppressive agent with beneficial effects on the neurological symptoms of EAE.

  7. Anecdotal support for effectiveness of scorpion sting in rheumatoid arthritis: an autoimmune disease 60 year old female living in Arizona with arthritis and severe joint pain in the knees. Had taken Clinirol for approximately 20 years, without which mobility was limited due to pain. Was stung by a bark scorpion on inside of left upper leg on February 20, 2006. Sting was extremely painful for the entire day. However, the next day there was no pain and no "tingling". Three days later, patient had no pain in the knees and was able to climb and descend stairs with ease. The beneficial effects lasted about 5-6 weeks. The pain and swelling gradually returned. (Personal communication from patient)

  8. Scorpion-derived peptides blockers of Kv1.3 channels in effector memory T cells may have use in the treatment of multiple sclerosis, rheumatoid arthritis and other autoimmune diseases

More Related